SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

• Revenue in USD (TTM)140.39m
• Net income in USD101.33m
• Incorporated1999
• Employees29.00

• Location
  SCYNEXIS Inc1 Evertrust Plaza, 13Th FloorJERSEY CITY 07302-6548United StatesUSA
• Phone+1 (201) 884-5485
• Fax+1 (919) 544-8697
• Websitehttps://www.scynexis.com/